-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2009, Hans Clevers et .
In 2009, Hans Clevers et .
In recent years, research results in the field of organoids have continued, and many new types of organoids and more complex organoids have emerged, bringing more powerful tools to the fields of new drug research and development, precision
On April 25, 2022, researchers from CrownBio, Merus, and the Barcelona Institute of Science and Technology jointly published a paper entitled: Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR in Nature Cancer, a sub-journal of Nature × Research paper on LGR5 bispecific antibody with efficacy in epithelial tumo.
For the first time, the study screened more than 500 bispecific antibodies using a library of organoids from cancer patients, and found an EGFR × LGR5 bispecific antibody named MCLA-158, which can effectively inhibit theGrowth of colorectal cancer organoids and prevention of metastas.
In October 2021, Merus reported on the safety, tolerability and antitumor efficacy of a mid-stage clinical trial of its EGFR × LGR5 bispecific antibody named MCLA-158 in advanced head and neck squamous cell carcinoma (HNSCC) Active, 3 of 7 patients experienced a partial response, 1 of them achieved a complete response, and tumor shrinkage was observed in all 7 patien.
In October 2021, Merus reported on the safety, tolerability and antitumor efficacy of a mid-stage clinical trial of its EGFR × LGR5 bispecific antibody named MCLA-158 in advanced head and neck squamous cell carcinoma (HNSCC) Active, 3 of 7 patients experienced a partial response, 1 of them achieved a complete response, and tumor shrinkage was observed in all 7 patien.
MCLA-158 (Petosemtamab), a bispecific antibody that recognizes two proteins on the surface of cancer stem cells, EGFR and LGR5, EGFR promotes uncontrolled cell growth, while LGR5 is on the surface of cancer stem cells responsible for the spread of canc.
MCLA-158 inhibits the EGFR protein in cancer stem cells with the LGR5 marker, thereby blocking the growth and survival of cancer stem cells that cause cancer to spre.
MCLA-158 inhibits the EGFR protein in cancer stem cells with the LGR5 marker, thereby blocking the growth and survival of cancer stem cells that cause cancer to spre.
Previous studies have shown that MCLA-158 inhibits production in preclinical tumor models of head and neck tumors, esophageal tumors, and gastric tumors, as well as inhibits the growth and metastasis of colorectal cancer organoi.
To further develop and characterize this bispecific antibody, researchers at HUB Organoids (created by organoid pioneer Hans Clevers) established a large library of organoids, including organoids from colorectal cancer patients, from colorectal cancer metastases organoids to the liver as well as organoids from normal noncancerous tiss.
In the early stages of drug development, using organoids from patient tumor tissue can help identify therapeutic drugs that are effective in patients, even in tumors harboring specific mutatio.
In this study, the research team identified MCLA-158 from more than 500 bispecific antibodies in high-throughput screening of colorectal cancer patient-derived organoids and healthy colonic mucosa-derived organoi.
MCLA-158 has demonstrated therapeutic properties in preclinical models of several epithelial cancer types, such as growth inhibition of KRAS-mutant colorectal cancer, blockade of metastasis initiation, and inhibition of tumor grow.
MCLA-158 has demonstrated therapeutic properties in preclinical models of several epithelial cancer types, such as growth inhibition of KRAS-mutant colorectal cancer, blockade of metastasis initiation, and inhibition of tumor grow.
Paper link:
https:// Leave a message here